Definium Therapeutics (DFTX) Return on Capital Employed (2020 - 2026)
Definium Therapeutics (DFTX) reported Return on Capital Employed of 56.94% for Q1 2026, down 1285.0% year-over-year from 4.81% in Q1 2025, and up 6.93% on a QoQ basis from 61.19% in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of Return on Capital Employed data on file, last reported at 56.94% in Q1 2026.
- Quarterly Return on Capital Employed fell 1285.0% year-over-year to 56.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 56.94% (down 1285.0% YoY) and the FY2025 annual result came in at 54.63%, up 492.0% from the prior year.
- Return on Capital Employed advanced to 56.94% in Q1 2026 per DFTX's latest filing, from 61.19% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 3.1% in Q3 2022 and bottomed at 93.12% in Q4 2023.
- The 5-year median for Return on Capital Employed is 49.54% (2023), against an average of 48.7%.
- The widest annual swing landed in 2023, when Return on Capital Employed plunged 8042 bps; it then surged 5493 bps in 2024.
- Tracing DFTX's Return on Capital Employed over 5 years: stood at 42.1% in 2022, then plunged by 121 bps to 93.12% in 2023, then surged by 59 bps to 38.19% in 2024, then plunged by 60 bps to 61.19% in 2025, then increased by 7 bps to 56.94% in 2026.
- Per Business Quant, the three latest DFTX Return on Capital Employed figures stand at 56.94% (Q1 2026), 61.19% (Q4 2025), and 81.47% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -56.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.94% |
| Dec 31, 2025 | -61.19% |
| Sep 30, 2025 | -81.47% |
| Jun 30, 2025 | -56.11% |
| Mar 31, 2025 | -44.09% |
| Dec 31, 2024 | -38.19% |
| Sep 30, 2024 | -35.93% |
| Jun 30, 2024 | -39.34% |
| Mar 31, 2024 | -70.65% |
| Dec 31, 2023 | -93.12% |
| Sep 30, 2023 | -77.32% |
| Jun 30, 2023 | -71.19% |
| Mar 31, 2023 | -49.54% |
| Dec 31, 2022 | -42.10% |
| Sep 30, 2022 | 3.10% |
| Jun 30, 2022 | 2.87% |
| Mar 31, 2022 | -16.73% |
| Dec 31, 2021 | -12.29% |
| Dec 31, 2020 | -41.69% |